Cancer cells brought under control by scientists

Jan 13, 2011

Scientists at The University of Nottingham have brought cancer cells back under normal control -- by reactivating their cancer suppressor genes. The discovery could form a powerful new technology platform for the treatment of cancer of the breast and other cancers.

Breast cancer is diagnosed in about 1.4 million women throughout the world every year, with half a million dying from the disease. A common cause of cancer is when cells are altered or mutated and the body's tumour suppressor genes are switched off.

Research, published today in the Journal Molecular Cancer, reveals how Dr. Cinzia Allegrucci from the School of Veterinary Science and Medicine and Dr. Andrew Johnson in the Centre for Genetics and Genomics reactivated tumour suppressor genes and stopped the cancer from growing by treating them with Axolotl oocyte extract. After 60 days there was still no evidence of cancerous growth.

Cancers occur when the mechanisms that control normal are mutated. The process of cell division is controlled by specific genes and these are turned “on” or “off” depending on their function. Among the most important of these genes are tumour suppressor genes. These genes repress the development of cancers and normally act as a control point in the cell division cycle. Therefore, the switching off of tumour suppressor genes is a common cause of cancers, including .

Dr. Allegrucci, a lecturer in molecular genetics and cell biology, said: “The on/off switch in genes is controlled by the modification of proteins that are bound to the DNA in a cell — so called epigenetic modifications. Tumour suppressor genes in many breast cancers are switched off by epigenetic marks, which is the underlying cause of tumours. We sought to reverse this process, activating the tumour suppressor genes, in hope of stopping cancerous cell divisions.”

Dr. Johnson said: “To do this we used novel technology that makes use of the eggs of the axolotl salamander. Over the years Dr. Johnson’s lab has shown that humans evolved from animals that closely resemble axolotls, and because of this the proteins in axolotls are very similar to those in humans. Axolotl oocytes — which are the eggs prior to ovulation — are packed with molecules that have very powerful epigenetic modifying activity. Previously Johnson’s lab showed that extracts prepared from these oocytes have powerful capacity to change epigenetic marks on the DNA of human cells.

And, in a breakthrough, they showed it is important to use oocytes from the ovary, because if the oocytes are ovulated these activities are lost. We thought that by treating with extracts made from axolotl oocytes we could reverse the epigenetic marks on tumour suppressor genes, causing these genes to reactivate, and thereby stopping the cancerous cell growth.”

The identification of the proteins responsible for this tumour reversing activity in axolotl oocytes is a major goal of future research which could form a powerful new technology platform for the treatment of cancers from the breast, and other tissues.

The University of Nottingham has a broad research portfolio but has also identified and badged 13 research priority groups, in which a concentration of expertise, collaboration and resources create significant critical mass. Key research areas at Nottingham include energy, drug discovery, global food security, biomedical imaging, advanced manufacturing, integrating global society, operations in a digital world, and science, technology & society.

Through these groups, Nottingham researchers will continue to make a major impact on global challenges.

Explore further: FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

Related Stories

New suppressor of common liver cancer

Dec 15, 2009

Tumor suppressor genes make proteins that help control cell growth. Mutations in these genes that generate nonfunctional proteins can contribute to tumor development and progression. One of the most well-known tumor suppressor ...

Genes associated with aggressive breast cancer

Aug 16, 2010

Researchers at the University of Gothenburg, Sweden, have for the first time identified 12 genes that could be associated with aggressive breast tumours. The discovery could result in more reliable prognoses and better treatment ...

Sorting the drivers from the passengers in the cancer genome

Feb 17, 2010

A new study of mutations in cancer genomes shows how researchers can begin to distinguish the 'driver' mutations that push cells towards cancer from the 'passenger' mutations that are a by-product of cancer cell development. ...

Recommended for you

Video: Is that double mastectomy really necessary?

5 minutes ago

When Angeline Vuong, 27,was diagnosed with cancer in one breast earlier this year, her first reaction was "A DOUBLE MASTECTOMY. NOW. " Turns out, she's far from alone: a recent JAMA study of 190,000 breast cancer cases in ...

FOLFOXIRI plus bevacizumab ups outcome in metastatic CRC

13 hours ago

(HealthDay)—For patients with untreated metastatic colorectal cancer, chemotherapy with fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab improves outcome versus fluorouracil, ...

User comments : 0